The short version of Freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-05. Anything still debated is marked as such rather than presented as settled.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised material; shade varies slightly between lots |
| Solubility in water | Freely soluble | Dissolves in water, saline, and aqueous buffers |
| Solubility in nonpolar solvents | Poorly soluble | Not compatible with oils or hydrocarbon solvents |
| Typical storage temperature | About −20 °C | Lyophilised, dry, dark storage slows hydrolysis |
| Common purity method | Reversed-phase HPLC | Area percentage, usually paired with mass spectrometry |
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
=== MeSH D12.644.456 – oligopeptides === MeSH D12.644.456.050 – amanitins MeSH D12.644.456.073 – angiotensins MeSH D12.644.456.073.021 – angiotensin i MeSH D12.644.456.073.041 – angiotensin ii MeSH D12.644.456.073.041.050 – angiotensin amide MeSH D12.644.456.073.041.800 – saralasin MeSH D12.644.456.073.041.815 – 1-sarcosine-8-isoleucine angiotensin ii MeSH D12.644.456.073.055 – angiotensin iii MeSH D12.644.456.073.070 – angiotensinogen MeSH D12.644.456.120 – antipain MeSH D12.644.456.193 – bradykinin MeSH D12.644.456.193.400 – kallidin MeSH D12.644.456.241 – caerulein MeSH D12.644.456.270 – chalones MeSH D12.644.456.300 – delta sleep-inducing peptide MeSH D12.644.456.345 – dipeptides MeSH D12.644.456.345.159 – anserine MeSH D12.644.456.345.190 – aspartame MeSH D12.644.456.345.331 – carnosine MeSH D12.644.456.345.360 – enalapril MeSH D12.644.456.345.360.300 – enalaprilat MeSH D12.644.456.345.575 – glycylglycine MeSH D12.644.456.345.600 – lisinopril MeSH D12.644.456.400 – n-formylmethionine leucyl-phenylalanine MeSH D12.644.456.448 – glutathione MeSH D12.644.456.448.500 – glutathione disulfide MeSH D12.644.456.448.750 – s-nitrosoglutathione MeSH D12.644.456.460 – gonadorelin MeSH D12.644.456.460.150 – buserelin MeSH D12.644.456.460.315 – goserelin MeSH D12.644.456.460.480 – leuprolide MeSH D12.644.456.460.600 – nafarelin MeSH D12.644.456.460.800 – triptorelin MeSH D12.644.456.580 – leupeptins MeSH D12.644.456.650 – netropsin MeSH D12.644.456.716 – pentagastrin MeSH D12.644.456.724 – pepstatins MeSH D12.644.456.726 – peptichemio MeSH D12.644.456.729 – peptide t MeSH D12.644.456.735 – phalloidine MeSH D12.644.456.745 – thyrotropin-releasing hormone MeSH D12.644.456.800 – tachykinins MeSH D12.644.456.800.354 – eledoisin MeSH D12.644.456.800.475 – kassinin MeSH D12.644.456.800.500 – neurokinin a MeSH D12.644.456.800.550 – neurokinin b MeSH D12.644.456.800.745 – physalaemin MeSH D12.644.456.800.866 – substance p MeSH D12.644.456.805 – technetium tc 99m mertiatide MeSH D12.644.456.810 – teprotide MeSH D12.644.456.830 – tetragastrin MeSH D12.644.456.835 – thymic factor, circulating MeSH D12.644.456.840 – tuftsin MeSH D12.644.456.925 – vasopressins MeSH D12.644.456.925.100 – argipressin MeSH D12.644.456.925.100.250 – deamino arginine vasopressin MeSH D12.644.456.925.325 – felypressin MeSH D12.644.456.925.480 – lypressin MeSH D12.644.456.925.700 – ornipressin MeSH D12.644.456.925.730 – oxytocin MeSH D12.644.456.925.940 – vasotocin
== Function == This gene encodes MC3R, a G-protein coupled receptor (GPCR) for melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) that is expressed in the brain. Early research suggests that humans who carry loss-of-function mutations in MC3R may have a somewhat later onset of puberty (roughly 5 months later for heterozygous girls). This along with evidence from animal models has led some researchers to propose that MC3R may have a role in regulating the timing of sexual maturity.
Packaged refrigerated or frozen red meat — to control pathogens (E. Coli O157:H7 and Salmonella) and to extend shelf life Packaged poultry — control pathogens (Salmonella and Camplylobacter) Fresh fruits, vegetables, and grains — to control insects and inhibit growth, ripening and sprouting Pork — to control trichinosis Herbs, spices and vegetable seasonings — to control insects and microorganisms Dry or dehydrated enzyme preparations — to control insects and microorganisms White potatoes — to inhibit sprout development Wheat and wheat flour — to control insects Loose or bagged fresh iceberg lettuce and spinach Crustaceans (lobster, shrimp, and crab) Shellfish (oysters, clams, mussels, and scallops)
Sources: en.wikipedia.org
The two substrates of this enzyme are β-D-glucose and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are D-glucono-1,5-lactone, reduced NADH, and a proton. The enzyme can alternatively use nicotinamide adenine dinucleotide phosphate (NADP+) for oxidation and in that case produces NADPH. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is beta-D-glucose:NAD(P)+ 1-oxidoreductase. Another name in common use is D-glucose dehydrogenase (NAD(P)+).
Additionally, FLAG-tags may be used in tandem, commonly the 3xFLAG peptide: DYKDHD-G-DYKDHD-I-DYKDDDDK (with the final tag encoding an enterokinase cleavage site). FLAG-tag can be fused to the C-terminus or the N-terminus of a protein, or inserted within a protein. Some commercially available antibodies (e.g., M1/4E11) recognize the epitope only when FLAG-tag is present at the N-terminus. However, other available antibodies (e.g., M2) are position-insensitive. The tyrosine residue in the FLAG-tag can be sulfated when expressed on certain secreted proteins, which can affect antibody recognition of the FLAG epitope. The FLAG-tag can be used in conjunction with other affinity tags, for example a polyhistidine tag (His-tag), HA-tag or myc-tag.
=== Mammals === Several groups of ungulates have independently reduced or lost side digits on their feet, often leaving one or two digits for walking. That name comes from their hooves, which have evolved from claws several times. For example, horses have one walking digit and domestic bovines two on each foot. Various other land vertebrates have also reduced or lost digits. Similarly, laurasiathere perissodactyls and afrothere paenungulates have several features in common, to the point of there being no obvious distinction among basal taxa of both groups. Many aquatic mammals or marine mammals independently came to have adaptations to live in water, such as similar-looking tail flukes in dugongs and whales. Unrelated herbivores and carnivores have adapted to marine and freshwater environments. The flipper forelimbs of marine mammals (cetaceans, pinnipeds, and sirenians) are a classic example of convergent evolution. There is widespread convergence at the gene level. Distinct substitutions in common genes created various aquatic adaptations, most of which also constitute parallel evolution because the substitutions in question are not unique to those animals. The pronghorn of North America, while not a true antelope and only distantly related to them, closely resembles the true antelopes of the Old World, both behaviorally and morphologically. It also fills a similar ecological niche and is found in the same biomes. Members of the two clades Australosphenida and Theria evolved tribosphenic molars independently.
== Further reading == Buckley RH (2004). "Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution". Annu Rev Immunol. 22: 625–55. doi:10.1146/annurev.immunol.22.012703.104614. PMID 15032591. Chinen J, Puck JM (2004). "Successes and risks of gene therapy in primary immunodeficiencies". J Allergy Clin Immunol. 113 (4): 595–603, quiz 604. doi:10.1016/j.jaci.2004.01.765. PMID 15100660. Church AC (2002). "X-linked severe combined immunodeficiency". Hosp Med. 63 (11): 676–80. doi:10.12968/hosp.2002.63.11.1914. PMID 12474613. Gennery AR, Cant AJ (2001). "Diagnosis of severe combined immunodeficiency". J Clin Pathol. 54 (3): 191–5. doi:10.1136/jcp.54.3.191. PMC 1731376. PMID 11253129.
Sources: en.wikipedia.org
Autosomal dominant: heart problems with weakness (and wasting) of skeletal muscles and Achilles tendon contractures. X-linked: result of the EMD gene mutation, characterized by cardiac involvement. Autosomal recessive: characterized by cardiac issues, such as arrhythmia.
Noriega's relationship with the U.S. deteriorated further during the late 1980s, particularly after the U.S. began to suspect that Noriega was supporting other intelligence services. Hersh wrote in 1986 that U.S. intelligence officials suspected that Noriega was selling intelligence to the Cuban government of Fidel Castro; his report received widespread attention. Bob Woodward published a story about Noriega in The Washington Post soon afterward, going into even greater detail about Noriega's intelligence connections. Woodward and Hersh's reputations made certain that the stories were taken seriously. Spadafora had also informed the U.S. Drug Enforcement Administration (DEA) of some of his findings about Noriega's involvement in drug smuggling. Multiple U.S. agencies continued to investigate Noriega despite opposition from the Reagan administration. In 1988 Noriega was indicted by U.S. federal grand juries in courts in Miami and Tampa on charges of drug-trafficking. The indictment accused him of "turning Panama into a shipping platform for South American cocaine that was destined for the U.S., and allowing drug proceeds to be hidden in Panamanian banks". Soon afterward an army colonel and a few soldiers made an attempt to overthrow Noriega; their poorly planned effort was crushed within a day. The presidential election of May 1989 was marred by fraud and violence. Coalición para la Liberación Nacional (Coalition for National Liberation), a pro-military coalition led by the PRD, named Carlos Duque, a former business partner of Noriega, as its candidate.
=== Reactivation and transplantation === The specific triggers for reactivation are not well understood. Some researchers have suggested that injury, physical or emotional stress, and hormonal imbalances could be involved. Researchers during 2011 discovered that reactivation can positively be triggered in vitro by histone deacetylase inhibitors. Once reactivation begins, the rolling circle process is initiated and concatemers are formed as described above. A study published in The Journal of Infectious Diseases in 2024 investigated the reactivation of inherited chromosomally integrated human herpesvirus 6 (iciHHV-6B) in a liver transplant recipient and its impact on the graft. The research, conducted by Hannolainen et al., used hybrid capture sequencing and various molecular techniques to analyze the viral sequences and host immune response. The findings demonstrated active replication of iciHHV-6B and significant immune activation, suggesting the pathological impact of viral reactivation on transplant outcomes. The study emphasizes the importance of monitoring iciHHV-6 reactivation in transplant patients.
Sources: en.wikipedia.org
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.
Reversed-phase HPLC is the standard approach, with purity expressed as a percentage of total peak area. Mass spectrometry confirms the expected molecular mass and can reveal adducts or truncated sequences. Neither method on its own establishes biological activity.
Small mass differences often reflect different counterions, such as acetate versus trifluoroacetate, or bound water rather than a different amino acid sequence. Mass spectrometry can distinguish these forms when the ionisation conditions are known. Exact sequence confirmation requires peptide mapping or tandem mass spectrometry.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.